KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Income (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Operating Income for 11 consecutive years, with -$154.8 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 139.62% to -$154.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$664.6 million through Dec 2025, down 42.44% year-over-year, with the annual reading at -$664.6 million for FY2025, 42.44% down from the prior year.
  • Operating Income hit -$154.8 million in Q4 2025 for CRISPR Therapeutics AG, down from -$132.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $762.6 million in Q2 2021 to a low of -$229.3 million in Q2 2025.
  • Historically, Operating Income has averaged -$82.7 million across 5 years, with a median of -$132.2 million in 2023.
  • Biggest five-year swings in Operating Income: soared 1045.13% in 2021 and later plummeted 192.82% in 2024.
  • Year by year, Operating Income stood at -$145.7 million in 2021, then increased by 9.72% to -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then tumbled by 139.62% to -$154.8 million in 2025.
  • Business Quant data shows Operating Income for CRSP at -$154.8 million in Q4 2025, -$132.1 million in Q3 2025, and -$229.3 million in Q2 2025.